Scandion Oncology udvikler anti-cancer lægemidler

26 June 2019 - 17:36
Scandion Oncology udvikler lægemidler, som kan blokere eller omgå resistens overfor anti-cancer lægemidler. Administrerende direktør Nils præsenterer firmaet for investorer....
Nasdaq First North GM (Sweden)
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...
Learn more about company

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More